ORAL ANTICOAGULANTS

Safety, efficacy, and safer everyday use

Audience: RN/APRN | **Contact hrs:** 1.6 | **Pharmacology hrs:** 1.5

Expected revision: October 5, 2028

Pharmacology hours are included in the total contact hours.

The benefit is real; safety is an active process

A patient may take an anticoagulant correctly for months and become vulnerable after three days of vomiting, a new interacting medicine, or an unplanned interruption. Another may leave the hospital with the right drug but the wrong treatment-phase dose. These are not failures of the drug's mechanism. They are failures to connect the prescription with the patient's changing circumstances. Safe oral anticoagulation requires that connection at every transition (Steffel et al., 2021).

Direct oral anticoagulants (DOACs), also called non–vitamin K antagonist oral anticoagulants, have changed stroke prevention and venous thromboembolism treatment. They remove the need for routine international normalized ratio (INR)–guided dose adjustment, but they do not remove the need for clinical review. This article examines how to preserve antithrombotic benefit while preventing avoidable bleeding, undertreatment, and administration errors. Five fictional cases illustrate the reasoning behind safer decisions (Crawford, 2023; American Heart Association [AHA], 2026).

Purpose, audience, and learning outcomes

This adult-care activity is intended for registered nurses and advanced practice registered nurses. Its purpose is to improve medication verification, surveillance, patient teaching, and escalation. U.S. prescribing information anchors the dosing examples; European guidance is identified when used. Product approvals, available reversal agents, and local requirements differ internationally. RNs implement authorized nursing and medication pathways; diagnostic, prescribing, interruption, and restart decisions require the appropriate clinician's authorization.

After completing the activity, the learner should be able to: explain the therapeutic roles and mechanisms of oral anticoagulants; compare pivotal efficacy and bleeding findings without overinterpreting indirect comparisons; verify an adult regimen against its indication, treatment phase, renal function, and interactions; prioritize assessment and escalation for suspected anticoagulant-associated bleeding; identify hazards during procedures, switching, and care transitions; and construct an individualized adherence, education, and follow-up plan.

Safety means balancing two preventable outcomes, not simply choosing the smallest dose. Excess exposure can contribute to bleeding, while omitted or inappropriately reduced treatment can leave the patient unprotected from stroke or recurrent venous thromboembolism. A high bleeding-risk score should prompt correction of modifiable risks and closer follow-up rather than automatically replacing indicated anticoagulation with aspirin (Crawford, 2023).

Understand what the drug is preventing

Hemostasis begins with a platelet response at an injured vessel and continues with thrombin generation and fibrin formation. Fibrin strengthens the initial platelet plug. Anticoagulants reduce formation or activity of coagulation proteins; antiplatelet drugs interfere with platelet activation or aggregation. Neither class is interchangeable with the other. Anticoagulants do not directly dissolve an established clot; treatment limits extension and recurrence while the body's endogenous processes act. Figure 1 connects the drug targets with clot stabilization (Steffel et al., 2021).

Warfarin inhibits vitamin K recycling and thereby reduces production of functionally active factors II, VII, IX, and X, as well as proteins C and S. Its effect changes gradually because already circulating proteins must turn over. The same prescribed dose can produce different effects as diet, interacting drugs, illness, or liver function changes. INR monitoring is therefore a treatment tool, not simply a surveillance test. For most AF and VTE indications the usual INR target range is 2.0–3.0; valve-specific targets require a separate plan (Steffel et al., 2021).



Figure 1. Oral anticoagulant targets in clot formation. Simplified original schematic; platelet and fibrin elements are not to scale.
Content: Steffel et al. (2021); BI (2025); BMS/Pfizer (2026); DS (2023); Janssen (2026).

Dabigatran directly inhibits thrombin, the enzyme that converts fibrinogen to fibrin. Apixaban, rivaroxaban, and edoxaban directly inhibit factor Xa, reducing downstream thrombin generation. Their relatively rapid onset supports fixed, indication-based regimens. Their shorter persistence compared with warfarin also makes missed doses clinically important. A fixed dose is a tested regimen for a defined population, not permission to ignore renal function, absorption, or concomitant medicines (Boehringer Ingelheim Pharmaceuticals, Inc. [BI], 2025; Bristol Myers Squibb & Pfizer [BMS/Pfizer], 2026; Daiichi Sankyo, Inc. [DS], 2023; Janssen Pharmaceuticals, Inc. [Janssen], 2026).

Atrial fibrillation and venous thromboembolism are different indications

In atrial fibrillation (AF), anticoagulation prevents stroke and systemic embolism in patients whose thromboembolic risk justifies treatment. Selection is based on risk and clinical context, not solely on whether AF is intermittent or continuously present. In eligible patients, contemporary U.S. guidance generally favors a DOAC over warfarin. Mechanical heart valves and clinically significant mitral stenosis are important exceptions; the broad phrase “valvular disease” is too imprecise to make the decision (Crawford, 2023).

Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism (PE). Treatment has an initial phase, a continuing treatment phase, and, for selected patients, extended prevention. The duration depends on the provoking circumstances, recurrence risk, bleeding risk, cancer status, and preferences. The 2026 multisociety acute PE guideline favors DOACs over vitamin K antagonists in eligible patients. Hemodynamically unstable PE is not a routine outpatient tablet-selection problem; urgent risk assessment and an acute treatment pathway take priority (AHA, 2026).

Low-dose rivaroxaban used with aspirin for selected coronary or peripheral artery disease is a separate strategy. The 2.5 mg twice-daily vascular dose is not an AF stroke-prevention dose or an acute VTE treatment dose. An aneurysm, a coronary diagnosis, or a prosthetic valve label on the problem list does not by itself establish that any DOAC regimen is appropriate.

Identify the exact indication before verifying the prescription (Janssen, 2026; Crawford, 2023).

Read comparative evidence without inventing a ranking

The pivotal AF trials established that the four DOACs could provide effective alternatives to warfarin in their studied populations. Their common clinical question was prevention of stroke or systemic embolism, but baseline risks, trial design, warfarin control, and safety definitions differed. Noninferiority means that a prespecified comparison excluded an unacceptable loss of efficacy; it does not mean two treatments are identical. Superiority on one endpoint does not guarantee superiority on every outcome. Table 1 summarizes the principal trial lessons (Connolly et al., 2009; Patel et al., 2011; Granger et al., 2011; Giugliano et al., 2013).

RE-LY compared two dabigatran regimens with warfarin. The 150 mg twice-daily regimen reduced stroke or systemic embolism with a similar overall major-bleeding rate. The 110 mg twice-daily regimen was noninferior for efficacy with less major bleeding. Both reduced intracranial hemorrhage; the 150 mg regimen had more gastrointestinal bleeding. The 110 mg twice-daily AF regimen used internationally must not be imported into U.S. prescribing as an approved AF regimen (Connolly et al., 2009; BI, 2025).

ROCKET AF established rivaroxaban's noninferiority to warfarin for stroke or systemic embolism. Superiority was not established in the intention-to-treat analysis. Intracranial and fatal bleeding were less frequent, while gastrointestinal bleeding was more frequent. ARISTOTLE showed that apixaban reduced stroke or systemic embolism and major bleeding relative to warfarin. These findings support selection discussions, but they do not constitute a randomized comparison between apixaban and rivaroxaban (Patel et al., 2011; Granger et al., 2011).

ENGAGE AF–TIMI 48 evaluated higher- and lower-dose edoxaban strategies, with protocol-defined dose reductions. The higher-dose strategy was noninferior to warfarin and produced less major bleeding, although gastrointestinal bleeding was increased. A trial arm starting at 30 mg and reducing to 15 mg is not the same as the U.S. labeled 60 mg regimen reduced to 30 mg for an eligible patient. Confusing a research strategy with a labeled dose is a medication-safety error (Giugliano et al., 2013; DS, 2023).

Across these trials, the reduction in intracranial bleeding compared with warfarin is an important advantage. Gastrointestinal bleeding is more dependent on the agent, dose, and patient. A patient with a prior ulcer therefore needs more than a general statement that DOACs are safer. The team should examine the lesion, anemia, renal function, concurrent antiplatelets, and the continuing indication for treatment (Connolly et al., 2009; Patel et al., 2011; Granger et al., 2011; Giugliano et al., 2013).

Network comparisons and observational studies can help clinicians ask better questions about relative outcomes. They cannot fully eliminate differences in who received each treatment, adherence, unmeasured illness, or outcome ascertainment. Do not promise a universally "safest" agent or assume that a relative risk reduction predicts a particular patient's absolute benefit. The useful conclusion is a patient-specific choice with a clear plan to correct modifiable risks and monitor performance (Steffel et al., 2021).

Warfarin remains an appropriate therapy when its indication, access, monitoring, and patient circumstances favor it. Stable INR control should not be dismissed merely because a newer drug exists. Conversely, persistently poor INR control warrants assessment of adherence, interactions, diet, and the feasibility of a suitable alternative. A switch should solve an identified problem rather than create a new affordability or dosing problem (Steffel et al., 2021).

Build a usable baseline before the first dose

The first verification is clinical: What event or risk is being treated, and what is the intended duration? Confirm AF-related prevention, current VTE treatment, extended prevention, postoperative prophylaxis, or another specific indication. Review the actual prescription against that indication and the patient's current treatment phase. An old medication list may contain a correct dose for an earlier phase but an incorrect dose for today (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

Obtain a baseline complete blood count, including hemoglobin and platelets, and assess renal and hepatic function. Record a measured body weight and relevant bleeding history. Ask about prior intracranial hemorrhage, gastrointestinal lesions, recent operations,

Table 1. Pivotal AF trials: the result and the limit of the inference

Trial / drug	Efficacy versus warfarin	Principal safety lesson	Interpretation safeguard
RE-LY Dabigatran	150 mg twice daily: superior for stroke/systemic embolism. 110 mg: noninferior.	Less intracranial bleeding with both regimens; 150 mg had more GI bleeding.	Do not import 110 mg twice daily as a U.S.-approved AF regimen.
ROCKET AF Rivaroxaban	Noninferior; no superiority in the intention-to-treat analysis.	Less intracranial/fatal bleeding; more GI bleeding.	An on-treatment result does not establish intention-to-treat superiority.
ARISTOTLE Apixaban	Superior for stroke/systemic embolism.	Less major and intracranial bleeding.	This was not a randomized comparison with every other DOAC.
ENGAGE AF Edoxaban	Both tested strategies were noninferior during treatment.	Less major bleeding; higher-dose strategy had more GI bleeding.	Do not treat the lower-dose research arm as a universal dose-reduction rule.

These are within-trial comparisons, not a head-to-head DOAC ranking. GI = gastrointestinal. Sources: Connolly et al. (2009); Patel et al. (2011); Granger et al. (2011); Giugliano et al. (2013).

falls or head injuries, abnormal uterine bleeding, and current symptoms. An unexplained low hemoglobin deserves an explanation before it is treated as an acceptable baseline. Normal baseline laboratory results do not guarantee safety after the patient's condition changes (Steffel et al., 2021).

Medication reconciliation must capture actual use, not just active electronic orders. Include aspirin, other antiplatelets, nonsteroidal anti-inflammatory drugs (NSAIDs), prescribed and nonprescribed products, herbal preparations, and medicines obtained from another prescriber. Determine whether a parenteral anticoagulant, warfarin, or a second DOAC is still being administered. Intentional overlap is limited to specific conversion or treatment plans; undocumented duplicate anticoagulation is not a routine precaution (Steffel et al., 2021).

A bleeding-risk score can organize the review, but it does not replace judgment or function as an automatic stop rule. Correct uncontrolled blood pressure, unnecessary antiplatelet therapy, excess alcohol exposure, and treatable bleeding lesions. Frailty and a history of falls require fall-prevention and adherence support, not automatic exclusion from anticoagulation. At the same time, severe recurrent injury, limited prognosis, or a recent major bleed may change the net benefit and warrant an individualized discussion (Crawford, 2023; Steffel et al., 2021).

Ask the patient to describe a normal day and the proposed dosing times. Can the medicine be obtained reliably? Is twice-daily administration feasible? Is a meal available when rivaroxaban requires it? Can capsules be swallowed? Will a caregiver participate? Choosing a theoretically attractive drug that the patient cannot consistently take is not a complete treatment decision. These questions are clinical safety checks, not optional discharge conveniences (Steffel et al., 2021; Janssen, 2026).

Active pathological bleeding is a contraindication to starting or continuing a DOAC without urgent reassessment. Mechanical valves, significant mitral stenosis, pregnancy, advanced organ dysfunction, and high-risk antiphospholipid syndrome need a disease-specific plan rather than default DOAC selection. Document what the prescriber has decided and why. When an RN identifies a discrepancy, the safe action is to clarify it before administration using the institution's escalation pathway (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

Match the dose to the indication and the calendar

Tables 2 and 3 separate common adult U.S. AF and VTE regimens. They are verification aids, not complete prescribing references. Interaction restrictions, severe organ dysfunction, and special-population decisions still



Figure 2. Initial and continuing adult VTE treatment phases. Do not substitute an AF reduction rule or an extended-prevention dose for an acute VTE regimen.

Content: BI (2025); BMS/Pfizer (2026); DS (2023); Janssen (2026).

require the full current label. A prescription should identify the drug, strength, dose, frequency, indication, start date, and, when relevant, the exact date of the next phase change. Figure 2 shows why the calendar is part of the prescription (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

Apixaban: do not borrow AF reduction criteria for acute VTE

For adult AF, the usual apixaban dose is 5 mg twice daily. The labeled dose is 2.5 mg twice daily when at least two criteria are present: age at least 80 years, body weight no more than 60 kg, and serum creatinine at least 1.5 mg/dL. Age alone is not this reduction rule. For acute DVT or PE, treatment is 10 mg twice daily for seven days and then 5 mg twice daily; the AF age–weight–creatinine rule must not be used to replace that initial regimen (BMS/Pfizer, 2026).

CASE 1 · Two criteria, not a general "elderly dose"

An 82-year-old woman with AF weighs 58 kg and has a serum creatinine of 1.2 mg/dL. Her prescriber orders apixaban 2.5 mg twice daily. She meets the age and weight criteria even though creatinine is below 1.5 mg/dL. The nurse verifies the indication, weight, renal assessment, and interaction review rather than rejecting the dose because only the creatinine value was considered.

The same 2.5 mg twice-daily prescription would not be a routine starting treatment for a newly diagnosed PE. The lesson is to identify which dosing rule applies before counting criteria. Document the criteria and indication together so that the next clinician can reconstruct the decision (BMS/Pfizer, 2026).

After at least six months of treatment for DVT or PE, apixaban 2.5 mg twice daily is a labeled option for

Table 2. Common adult U.S. AF doses and high-consequence checks

Drug	AF stroke/systemic embolism prevention	Critical check
Apixaban	5 mg twice daily. Use 2.5 mg twice daily when ≥2: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL.	Age alone is not the reduction rule. Strong combined P-gp/CYP3A inhibitors need separate label review.
Rivaroxaban	20 mg once daily with the evening meal if CrCl >50 mL/min; 15 mg once daily with the evening meal if CrCl ≤50.	Review advanced kidney disease separately. Do not use the 2.5 mg vascular regimen for AF.
Dabigatran	150 mg twice daily if CrCl >30 mL/min; 75 mg twice daily if CrCl 15–30. No dose recommendation below 15 or on dialysis.	Renal function and P-gp interactions act together. The severe-renal AF dose is not an established VTE dose.
Edoxaban	60 mg once daily if CrCl >50 to ≤95 mL/min; 30 mg once daily if CrCl 15–50.	Do not use for AF if CrCl >95 mL/min. Not recommended if CrCl <15. VTE weight reduction rules are different.

CrCl is in mL/min. These are common label regimens, not a complete prescribing table. Advanced renal/hepatic disease and interactions require full-label review. Sources: BI (2025); BMS/Pfizer (2026); DS (2023); Janssen (2026).

reducing recurrence. That is a treatment-phase decision, not proof that a patient's original VTE was mild. Apixaban may be taken with or without food. Its tablets have labeled crushed-tablet administration options, including delivery through a nasogastric tube; follow the product's preparation and tube instructions rather than extrapolating from another drug (BMS/Pfizer, 2026).

Rivaroxaban: food and phase changes matter

For adult AF, rivaroxaban is taken once daily with the evening meal: 20 mg when creatinine clearance (CrCl) is above 50 mL/min and 15 mg when it is 50 mL/min or less, with additional label review for advanced kidney disease. Acute DVT or PE treatment starts with 15 mg twice daily with food for 21 days, followed by 20 mg once daily with food. For adult VTE, the label permits these regimens at CrCl at least 15 mL/min, while recognizing limited trial data below 30; avoid use below 15 (Janssen, 2026).

CASE 2 · The day-22 handoff

A 64-year-old man treated for a stable PE is approaching the end of his rivaroxaban starter phase. He has the 15 mg tablets but has not collected the 20 mg prescription. He believes he should continue one 15 mg tablet each morning after day 21 because "the dose becomes once a day."

The nurse identifies a strength-and-frequency error before it happens, contacts the prescribing team and pharmacy, and confirms the ordered day-22 transition to 20 mg once daily with food. The written plan gives the last twice-daily date and first once-daily date. The patient repeats both dates and describes how he will obtain the next supply. An accurately reconciled list alone would not have exposed the access problem (Janssen, 2026).

Rivaroxaban 10 mg once daily after at least six months of standard VTE treatment is a separate labeled recurrence-prevention option. The 10 mg and 2.5 mg tablets do not require food, but 15 mg and 20 mg doses do. A crushed 15 mg or 20 mg dose must be followed promptly by food or enteral feeding. Tube delivery must be into the stomach; administration distal to the stomach can reduce exposure. Check tube position and formulation instructions before giving it (Janssen, 2026).

Dabigatran and edoxaban: confirm the lead-in

Dabigatran and edoxaban are not oral-only starting regimens for acute adult DVT or PE. Each requires five to ten days of initial parenteral anticoagulation before the oral treatment regimen. Dabigatran's adult VTE dose is 150 mg twice daily when CrCl is above 30 mL/min; the U.S. label does not provide a VTE dose at CrCl 30 or below. Its 75 mg twice-daily severe-renal-impairment AF regimen must not be

Table 3. Adult U.S. VTE regimens: initial, continuing, and extended treatment

Drug	Initial treatment	Continuing treatment	Extended prevention
Apixaban	10 mg twice daily for 7 days.	5 mg twice daily from day 8.	2.5 mg twice daily after ≥6 months of DVT/PE treatment.
Rivaroxaban	15 mg twice daily WITH FOOD for 21 days.	20 mg once daily WITH FOOD from day 22.	10 mg once daily after ≥6 months of standard treatment.
Dabigatran	Parenteral anticoagulant for 5–10 days.	Then 150 mg twice daily when CrCl >30 mL/min.	150 mg twice daily in eligible adults; no U.S. reduced-dose VTE prevention regimen.
Edoxaban	Parenteral anticoagulant for 5–10 days.	Then 60 mg once daily; 30 mg if CrCl 15–50, weight ≤60 kg, or specified P-gp inhibitors.	Continue the indication-appropriate regimen if ongoing treatment is selected.

Eligibility and duration require individualized review. Adult rivaroxaban VTE use: CrCl ≥15; below 30, outcome data are limited. Dabigatran VTE: no dose recommendation for CrCl ≤30. Apixaban advanced renal disease requires separate evidence/label review. Sources: BI (2025); BMS/Pfizer (2026); DS (2023); Janssen (2026).

repurposed as an established VTE dose (BI, 2025; DS, 2023).

Dabigatran capsules must be swallowed intact. Opening, chewing, or crushing changes exposure and is unsafe. Keep capsules in their original manufacturer container or blister packaging to protect them from moisture, following the label's storage instructions. Dyspepsia can undermine adherence; ask specifically about symptoms rather than assuming a refill proves regular use. A patient who cannot swallow the capsule needs a formulation or treatment review, not an improvised feeding-tube mixture (BI, 2025).

Edoxaban is generally 60 mg once daily, but the reduction rules differ by indication. For AF, reduce to 30 mg once daily for CrCl 15–50 mL/min and do not use edoxaban when CrCl exceeds 95 mL/min because of reduced efficacy relative to warfarin. For VTE, reduce to 30 mg once daily when CrCl is 15–50, weight is no more than 60 kg, or specified P-glycoprotein inhibitors are used. Do not automatically transfer the VTE weight rule to an AF prescription (DS, 2023).

No routine INR does not mean no monitoring

All four DOACs depend on renal elimination to some degree, especially dabigatran. A creatinine value can appear unremarkable in an older adult with low muscle mass even when renal drug clearance is impaired. Use the renal method on which the relevant dose recommendation is based. Cockcroft–Gault CrCl was used in the pivotal DOAC trials and remains important for label-based verification; the laboratory's indexed estimated glomerular filtration rate is not automatically interchangeable (Steffel et al., 2021).

For a stable adult, the conventional Cockcroft–Gault calculation uses age, body weight, and serum creatinine, with the original female coefficient when applicable. The result is expressed in mL/min, not mL/min/1.73 m². Weight selection in severe obesity or underweight needs a consistent pharmacy-approved method. Do not arbitrarily round a low creatinine upward. During acute kidney injury, creatinine is changing and a steady-state equation may misrepresent current clearance. The clinical trend and an urgent prescribing review matter more than a falsely precise calculated result (Steffel et al., 2021).

CASE 3 · A normal INR cannot clear dabigatran

A 78-year-old woman weighing 60 kg takes dabigatran 150 mg twice daily for AF. Her stable serum creatinine had been 1.2 mg/dL. After vomiting and poor intake it rises to 2.0 mg/dL. Using the conventional female coefficient, the calculated CrCl changes from about 36.6 to 22.0 mL/min. Because renal function is changing,



Figure 3. Clinical condition, clearance, and residual drug are different questions. Acute kidney injury can invalidate a steady-state clearance estimate.

Content: Steffel et al. (2021); Barnes (2020); current product labels.

> neither number should be treated as a precise current steady-state clearance.
>
> She reports dark stools, and the INR is 1.1. The nurse escalates suspected bleeding and acute renal deterioration, obtains the actual last-dose time, and follows the urgent medication-hold and assessment pathway. A normal INR does not exclude dabigatran activity. Automatically changing to the AF 75 mg dose would not resolve the immediate problem of possible bleeding and accumulation (BI, 2025; Steffel et al., 2021; Barnes, 2020).

Figure 3 separates three questions that are often confused: Is the patient bleeding or thrombosing? Is drug clearance changing? Is a clinically important drug concentration likely to remain? Hemoglobin helps assess blood loss; renal tests inform accumulation risk; a drug-specific assay can answer an exposure question in selected urgent situations. None substitutes for the others. A single normal value should not override an evolving clinical picture (Steffel et al., 2021; Barnes, 2020).

The EHRA practical guide suggests at least yearly hemoglobin, renal, and hepatic testing for otherwise stable patients, with more frequent testing in older or frail patients. Its practical schedule includes approximately four-monthly testing for patients at least 75 years old or frail, and a CrCl/10 rule to guide the interval in months when CrCl is 60 mL/min or less. These are follow-up aids, not permission to wait when dehydration, infection, bleeding, or a medication change occurs (Steffel et al., 2021).

Routine PT/INR and activated partial thromboplastin time cannot reliably quantify every DOAC's anticoagulant effect. A normal INR must not be used to rule out a clinically significant factor Xa inhibitor level. Drug-calibrated anti-Xa assays can assess apixaban, rivaroxaban, or edoxaban when available. Dilute thrombin time or an ecarin-based assay can help assess dabigatran. Interpretation depends on assay sensitivity, calibration, the drug, sampling time, and last dose; consult the laboratory rather than applying a warfarin target (Barnes, 2020; Steffel et al., 2021).

Advanced chronic kidney disease and dialysis require individualized decisions. Trial exclusion thresholds, regulatory doses based on pharmacokinetics, and guideline-supported options are not equivalent evidence. For example, the apixaban label contains renal-use provisions, but major efficacy trials did not establish outcomes across all dialysis or very low CrCl populations. Do not teach either that every DOAC is forbidden below one universal threshold or that a labeled dose guarantees equal evidence in every indication (BMS/Pfizer, 2026; BI, 2025; DS, 2023; Janssen, 2026).

Hepatic disease can alter both drug handling and the underlying balance of coagulation. Rivaroxaban should be avoided in moderate or severe hepatic impairment and hepatic disease associated with coagulopathy. Apixaban is not recommended in severe hepatic impairment; its label does not provide a dosing recommendation for moderate impairment. Edoxaban is not recommended in moderate or severe hepatic impairment. A high INR from liver disease is not a reliable measure of DOAC exposure or proof that the patient is protected from thrombosis (BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

Look for additive bleeding and altered exposure

Interactions operate through different mechanisms. Aspirin, P2Y12 inhibitors, NSAIDs, and other anticoagulants can add bleeding risk without substantially changing the DOAC concentration. Strong inhibitors of transport or metabolism can increase exposure, while inducers can reduce it and compromise efficacy. Separating medicines by a few hours usually does not solve a sustained enzyme or transporter interaction. The response must be drug-specific (Steffel et al., 2021).

Apixaban and rivaroxaban are affected by P-glycoprotein and CYP3A pathways. Strong combined inhibitors, such as certain systemic azoles or ritonavir-containing regimens, require careful label-based management. The apixaban label calls for a 50% dose reduction with specified strong combined inhibitors when the patient is taking 5 or 10 mg twice daily; avoid the combination if the patient already receives 2.5 mg twice daily. Rivaroxaban generally should not be combined with strong combined P-glycoprotein/CYP3A inhibitors (BMS/Pfizer, 2026; Janssen, 2026).

Strong inducers such as rifampin, carbamazepine, phenytoin, or St. John's wort can reduce exposure to susceptible DOACs. A dose should not be increased empirically to compensate. Dabigatran is particularly sensitive to the combination of renal impairment and P-glycoprotein inhibition. Its U.S. interaction adjustments differ between AF and VTE; edoxaban's P-glycoprotein reduction rules also differ by indication. Ask pharmacy to review the exact pair, dose, indication, and renal function (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

Moderate interactions are not automatically harmless, especially when several risk factors coexist. An older patient with declining kidney function, low weight, and a newly prescribed interacting drug deserves a fresh review even when no single item seems decisive. Include short courses of anti-infective treatment in reconciliation. A temporary prescription can outlast the hospital encounter and alter risk at home (Steffel et al., 2021).

Antiplatelets need an indication and an end point

After acute coronary syndrome or coronary stenting, AF may create a need for both anticoagulation and antiplatelet therapy. AUGUSTUS tested apixaban versus a vitamin K antagonist and aspirin versus placebo in patients receiving a P2Y12 inhibitor. Apixaban produced less major or clinically relevant nonmajor bleeding than a vitamin K antagonist, and aspirin increased bleeding relative to placebo. These findings support minimizing unnecessary combination treatment, but do not mean that every patient should omit aspirin immediately after PCI regardless of ischemic risk (Lopes et al., 2019).

The cardiology plan should specify each antithrombotic's purpose and planned duration. For AF with chronic coronary disease beyond one year after revascularization, and without prior stent thrombosis, U.S. guidance generally favors anticoagulant monotherapy over continued addition of an antiplatelet agent. A remote stent is therefore a reason to review persistent aspirin, not an automatic reason to continue it indefinitely or for a nurse to stop it without an order (Crawford, 2023).

Ask explicitly about over-the-counter ibuprofen, naproxen, aspirin-containing combination products, and supplements. Patients may not consider these "medications." Teach the patient to check with the treating team before starting a new product. For patients

who need more than one antithrombotic, review gastrointestinal risk and whether gastroprotection is appropriate. Preventing a medication-related bleed includes avoiding unnecessary exposure, not merely identifying bleeding after it starts (Steffel et al., 2021).

Treat the patient, not a reassuring laboratory result

Bleeding can be visible, concealed, or initially subtle. Melena, hematemesis, gross hematuria, new severe headache, focal neurological change, syncope, unexplained hypotension, or a rapidly enlarging painful swelling needs prompt assessment. Blood loss may present as weakness or dyspnea before the source is obvious. Anticoagulation may amplify bleeding from an ulcer, tumor, trauma, or another lesion; identifying the drug does not identify the source. Figure 4 connects warning signs with escalation (Barnes, 2020; Steffel et al., 2021).

An ACC major-bleeding framework includes bleeding at a critical site, hemodynamic instability, a hemoglobin fall of at least 2 g/dL, or a need for at least two units of red blood cells. These are alternative criteria, not a checklist that must all be satisfied. Intracranial bleeding or shock can be major before a measured hemoglobin drop is available. Do not wait for a numerical threshold to escalate an unstable patient (Barnes, 2020).

For significant suspected bleeding, promptly communicate the anticoagulant name, dose, indication, actual last administration time, kidney function, interacting drugs, and vital-sign trend. Activate the local emergency pathway, support airway and circulation, obtain appropriate access and blood work, and pursue source control. Temporarily withhold further anticoagulant doses under emergency policy or an authorized order. Imaging, endoscopy, surgery, interventional radiology, or specialist treatment may be needed. Reversal does not replace resuscitation or control of the lesion (Barnes, 2020).

CASE 4 · The old reversal order set

A 74-year-old man taking apixaban presents with hematemesis, blood pressure 82/48 mm Hg, heart rate 118/min, and new confusion. His last dose was three hours earlier. The INR is 1.1. The team activates the major-hemorrhage pathway, withholds further apixaban, begins resuscitation, and urgently arranges source assessment. The normal INR does not neutralize the clinical emergency.

An old electronic order set lists Andexxa as the default. Pharmacy flags the changed U.S. safety and supply status. The treating team selects the current locally available factor Xa inhibitor–associated bleeding protocol, including consideration of four-factor prothrombin complex concentrate when indicated. The nurse confirms the actual product, dose, and administration time rather than treating an electronic order as completed treatment (Barnes, 2020; U.S. Food and Drug Administration [FDA], 2025).

Reversal must match the anticoagulant

For warfarin-associated life-threatening or major bleeding requiring urgent reversal, four-factor prothrombin complex concentrate (4F-PCC) replaces deficient clotting factors rapidly, while vitamin K supports sustained reversal. Plasma is an alternative when the preferred concentrate is unavailable. INR and weight inform product-specific dosing. Vitamin K is not an antidote for dabigatran or factor Xa inhibitors. Do not delay an indicated emergency response while searching for a nonexistent vitamin K effect on a DOAC (Barnes, 2020).

Idarucizumab is the specific reversal agent for dabigatran when emergency surgery or an urgent procedure requires reversal, or when bleeding is life-threatening or uncontrolled. The standard dose is 5 g intravenously. It does not reverse apixaban, rivaroxaban, or edoxaban. Continue surveillance after treatment because bleeding can persist from the underlying lesion and anticoagulant activity can recur in selected circumstances, particularly with substantial residual drug burden. Restart decisions remain separate from successful initial reversal (Barnes, 2020; BI, 2025).

U.S. reversal teaching must reflect the FDA's December 2025 safety communication about andexanet alfa (Andexxa). The FDA concluded that serious risks, including thromboembolic events, outweighed its benefits; U.S. commercial sales ended on December 22, 2025. Older guidelines and order sets that automatically direct clinicians to Andexxa are therefore not a reliable statement of current U.S. availability. Product status in other jurisdictions must be checked separately (FDA, 2025).

For life-threatening factor Xa inhibitor–associated bleeding, follow the current institutional specialist and pharmacy pathway. 4F-PCC may be used as a



Figure 4. Warning signs and immediate priorities in suspected anticoagulant-associated bleeding. Source control and resuscitation accompany, rather than follow, the reversal decision.

Content: Barnes (2020); Steffel et al. (2021). Current U.S. factor Xa reversal availability: FDA (2025).

nonspecific hemostatic strategy; its use to reverse a DOAC is off-label, and it does not remove the circulating drug. Dose selection and repeat treatment require protocol-based expertise and assessment of thrombosis risk. Do not imply that nonspecific reversal has the same mechanism or evidence as a drug-binding antidote (Barnes, 2020; Steffel et al., 2021; FDA, 2025).

Activated charcoal has a limited, time-sensitive role after selected recent ingestions when the airway is protected and toxicology or specialist guidance supports it. Dialysis can remove dabigatran in selected circumstances, but it is not an effective general strategy for highly protein-bound factor Xa inhibitors. These measures should not distract from time-critical resuscitation, source control, or an indicated reversal agent. Routine recombinant factor VIIa is not a default DOAC reversal approach (BI, 2025; Steffel et al., 2021).

Minor bleeding and restarting treatment

Small bruises or brief gum bleeding call for assessment, local measures, medication review, and patient guidance; they do not routinely justify a reversal product or prolonged self-discontinuation. Recurrent epistaxis, hematuria, or heavy menstrual bleeding can be clinically important even without shock. Investigate persistent symptoms and their impact on adherence. Escalation intensity should reflect the site, persistence, blood loss, hemodynamics, and patient context (Steffel et al., 2021; Barnes, 2020).

Once bleeding is controlled, reassess why anticoagulation was prescribed and whether that indication remains. Many patients benefit from restarting when medically safe, while critical-organ bleeding or an unidentified source may require delay. There is no universal restart day for every gastrointestinal or intracranial event. The plan should state who will decide, what must be reassessed, and how the patient will avoid both accidental early resumption

and an unintended indefinite interruption (Barnes, 2020).

An interruption needs a stop plan and a restart plan

Periprocedural management depends on bleeding risk, the specific drug, kidney function, procedure timing, and thromboembolic risk. A simple instruction to stop "the blood thinner" two days beforehand is incomplete. Record the name and time of the last dose actually taken, not merely the planned last dose. A late dose, worsening renal function, or a change from a superficial procedure to a neuraxial technique may invalidate the original schedule. Figure 5 illustrates the required decision sequence (Douketis et al., 2019; Kopp et al., 2025).

In the PAUSE study, a standardized interruption-and-resumption approach in AF patients receiving apixaban, dabigatran, or rivaroxaban achieved low perioperative bleeding and arterial thromboembolism rates without routine heparin bridging. The protocol incorporated procedure risk and renal function, with longer interruption for selected dabigatran patients. Its lesson is the value of a structured plan; it is not a universal schedule for every procedure, severe renal impairment, emergency operation, or patient receiving treatment for a very recent VTE (Douketis et al., 2019).

Routine therapeutic heparin bridging is usually unnecessary during a brief planned DOAC interruption and can add bleeding risk. Exceptional thrombotic situations require specialist assessment rather than an automatic bridge order. Postoperative prophylactic-dose anticoagulation, when ordered because full treatment cannot yet resume, is a different decision from therapeutic bridging. Clarify both dose and purpose in the medication administration record (Douketis et al., 2019; Steffel et al., 2021).

Neuraxial procedures are a separate high-consequence pathway

Spinal or epidural bleeding can cause permanent neurological injury. The ASRA fifth-edition guidance uses drug-, dose-, and renal-function–specific precautions for regional anesthesia and catheter management. Do not use a general surgical hold interval to clear a neuraxial procedure. Catheter insertion, removal, traumatic puncture, and the next anticoagulant dose must be coordinated with the anesthesia team. New severe back pain, weakness, sensory change, or bowel or bladder dysfunction requires urgent neurological evaluation (Kopp et al., 2025; BI, 2025).

Restart only after the authorized team has considered hemostasis, procedure-related bleeding, catheter status, and the patient's ability to absorb the medicine. A calendar reminder is not an order to restart despite active bleeding. Conversely, "hold until further notice" without an owner and review time creates an avoidable thrombotic hazard. Handoff should include the earliest proposed restart, prerequisites, responsible clinician, and the next reassessment time (Douketis et al., 2019; Kopp et al., 2025).

Switching between agents is not a universal overlap rule

When changing from warfarin to a DOAC, the first dose depends on the current INR and selected product. U.S. labels use INR below 2.0 for apixaban or dabigatran, below 3.0 for rivaroxaban, and 2.5 or less for edoxaban. These thresholds are not interchangeable. Verify the last warfarin dose and actual INR, and give the patient a written stop/start plan that removes the previous drug from active home instructions (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

Conversion from a DOAC to warfarin is more complex because warfarin has a delayed onset and DOACs can influence the INR. Apixaban and rivaroxaban labels describe approaches involving a parenteral anticoagulant with warfarin; dabigatran timing depends on renal function, and edoxaban has its own options. Do not teach "overlap both tablets until INR is 2" as a rule for all agents. Use the exact product conversion instructions and pharmacist support (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

A switch between DOACs commonly begins when the next dose would have been due, but suspected accumulation, active bleeding, or deteriorating renal function may require a different plan. Similarly, transition to or from heparin depends on the prior drug, its infusion or dosing schedule, and residual effect. The safe handoff includes the last administered dose, not just a discontinued order, and the exact first dose of the replacement (Steffel et al., 2021).



Figure 5. A safer interruption and restart pathway. Generic surgical hold instructions must not replace neuraxial or catheter-specific guidance.

Content: Douketis et al. (2019); Kopp et al. (2025); Steffel et al. (2021).

Do not extrapolate beyond the population being treated

Cancer-associated thrombosis

Cancer-associated VTE no longer requires an automatic assumption that oral agents are unproven. In CARAVAGGIO, apixaban was noninferior to dalteparin for recurrent VTE, with major bleeding rates of 3.8% and 4.0%, respectively. Nevertheless, active gastrointestinal or genitourinary lesions, thrombocytopenia, vomiting, impaired absorption, interacting cancer therapy, and frequent procedures can favor low-molecular-weight heparin or another individualized approach. A trial average does not remove the need to examine the particular cancer and treatment regimen (Agnelli et al., 2020; Steffel et al., 2021).

API-CAT addressed extended treatment, not the first weeks of an acute event. Among patients with active cancer who had completed at least six months of anticoagulation for proximal DVT or PE, apixaban 2.5 mg twice daily was noninferior to 5 mg twice daily for recurrent VTE during a further year. Clinically relevant bleeding was lower with the reduced dose. The findings support reassessment of extended-dose intensity in eligible patients; they do not justify starting acute cancer-associated PE at 2.5 mg twice daily (Mahé et al., 2025).

CASE 5 · A lower dose at the right phase

A 61-year-old woman with active breast cancer has completed eight months of apixaban 5 mg twice daily after a PE. She has had no recurrence but describes repeated troublesome nosebleeds. Her oncology and anticoagulation teams reassess the bleeding source, cancer therapy, renal function, and continuing VTE risk.

The prescriber discusses reduced-dose apixaban for extended prevention, informed by the completed treatment duration and API-CAT evidence. The nurse reinforces the new authorized dose and removes conflicting old instructions. This is not an age-based reduction, and it cannot be copied to a patient who developed PE yesterday. The indication

and phase explain why the same tablet strength can be appropriate in one situation and inadequate in another (Mahé et al., 2025; BMS/Pfizer, 2026).

Valves, antiphospholipid syndrome, and body size

Mechanical heart valves require a separate anticoagulation strategy, generally involving a vitamin K antagonist; DOACs are not substitutes simply because INR monitoring is inconvenient. Significant mitral stenosis is another important exception to routine DOAC preference in AF. Bioprosthetic valves and prior valve repair are not identical to mechanical valves, but timing, indication, and specialist guidance still matter. Identify the actual valve type instead of making a decision from the word "prosthetic." (Crawford, 2023; BI, 2025).

DOAC labels warn against use in triple-positive antiphospholipid syndrome because of increased thrombotic risk compared with vitamin K antagonist therapy. A history of recurrent arterial events or suspected antiphospholipid syndrome warrants specialist review before a routine change from warfarin. At extremes of body weight, avoid an improvised dose reduction or escalation; examine the agent-specific evidence, renal estimate, and any absorption concerns, including prior bariatric surgery (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026; Steffel et al., 2021).

Pregnancy, lactation, and pediatric boundaries

Pregnancy and breastfeeding require a dedicated maternal or hematology plan; DOACs should not be treated as routine substitutes for pregnancy-appropriate anticoagulation. Warfarin also has important fetal risks, with complex exceptions requiring specialized management. Ask about pregnancy potential and plans before treatment changes, and direct an unexpected pregnancy to prompt review rather than instructing the patient to stop all anticoagulation without a replacement decision (BI, 2025; BMS/Pfizer, 2026; DS, 2023; Janssen, 2026).

The statement that no DOAC has a pediatric indication is obsolete. Current U.S. labeling includes pediatric uses for selected products, including rivaroxaban, dabigatran formulations, and apixaban. Those approvals are formulation-, age-, weight-, and indication-specific; they do not make adult doses appropriate for children. This activity's dosing tables are exclusively for adults. Pediatric prescribing and administration require the specific pediatric product instructions and specialist pathway (BI, 2025; BMS/Pfizer, 2026; Janssen, 2026).

Make the home plan executable

A prescription protects a patient only when the medicine is taken as intended. Ask about missed doses without blame: "Many people have difficulty fitting this medicine into their day. Which doses are hardest?" Check refill access, cost, work schedules, cognition, swallowing, dexterity, and caregiver availability. A once-daily regimen is not automatically more adherent, and a twice-daily regimen is not automatically unsuitable. Match practical support to the person rather than relying on dosing frequency alone (Steffel et al., 2021).

Teach the exact product-specific missed-dose instruction. For dabigatran, a missed dose may be taken only when at least six hours remain before the next scheduled dose; otherwise it is skipped, without doubling. For apixaban, take the missed dose as soon as possible on the same day and resume twice-daily dosing without doubling. For edoxaban, take it as soon as remembered that day and then resume the usual schedule, without doubling (BI, 2025; BMS/Pfizer, 2026; DS, 2023).

Rivaroxaban requires special attention because its missed-dose instruction changes with the regimen. During adult 15 mg twice-daily VTE treatment, the label allows two 15 mg tablets together when needed to ensure 30 mg is taken that day. For once-daily 10, 15, or 20 mg regimens, take the missed dose as soon as remembered on the same day, without doubling within that day to compensate. Do not simplify this into an unqualified instruction to double any anticoagulant (Janssen, 2026).

Give patients a recognizable emergency plan. Uncontrolled bleeding, vomiting blood, black stools accompanied by weakness or dizziness, new neurological symptoms, collapse, or a significant head injury needs urgent assessment. Tell the patient to identify the anticoagulant and last dose to emergency personnel. New symptoms of thrombosis, including sudden focal weakness, unexplained chest pain or breathlessness, or a painful swollen limb, also require prompt evaluation. An anticoagulant prescription does not rule out a new thrombotic event (BI, 2025; Janssen, 2026; AHA, 2026).

For minor bruising, do not encourage self-directed dose skipping. Explain whom to contact for persistent gum bleeding, nosebleeds, hematuria, or changes in menstrual bleeding. Before a procedure or dental visit, the patient should report the anticoagulant and seek a coordinated plan, not stop it independently. A wallet card or accessible medication record should include the drug, indication, dose, emergency contact, and relevant treatment-phase change (Steffel et al., 2021).

Warfarin teaching differs from DOAC teaching. Patients need an INR appointment and a current dosing calendar, including which tablet strengths are being used. Vitamin K intake should be reasonably consistent rather than eliminated. New medicines and major dietary or illness changes can alter anticoagulation and should trigger contact with the monitoring service. DOAC patients do not need a vitamin K–restricted diet, but their food, formulation, and interaction instructions remain important (Steffel et al., 2021; Janssen, 2026).

Use teach-back to verify actions, not merely recognition: “Show me what you will take tomorrow morning,” “What changes next Monday?” and “What will you do if the pharmacy cannot fill it?” The patient’s explanation may reveal confusion hidden by a signed instruction sheet. When a caregiver administers medicines, confirm that the caregiver has the same current schedule and knows which previous prescription has been discontinued.

At discharge, confirm that the next dose is available and that the first outpatient follow-up has an owner. Communicate the actual last hospital dose, renal trend, recent bleeding, ongoing antiplatelets, planned tests, and the intended duration or review date. At each subsequent review, reconsider indication, dose, renal and hepatic function, symptoms, interactions, and adherence. Monitoring is a continuing clinical relationship, not simply a laboratory reminder (Steffel et al., 2021).

Preserve protection while removing preventable harm

The safest anticoagulant is not necessarily the newest medicine, the lowest dose, or the agent with the most favorable average trial result. It is an appropriate treatment, given at the correct dose and phase, with foreseeable hazards actively managed. Verify indication before applying a dose rule. Interpret kidney function in context. Treat a normal INR as irrelevant reassurance when significant DOAC activity remains possible. Respond to major bleeding with coordinated resuscitation, source control, and a current reversal plan (Steffel et al., 2021; Barnes, 2020).

A safe interruption includes a responsible clinician and a restart decision. A safe discharge includes an obtainable medicine and a patient who can describe how to take it. A safe update distinguishes established evidence from uncertain extrapolation and current product status from an old order set. These practices connect anticoagulant efficacy with the daily nursing decisions that make its benefits more likely to reach the patient.

References

Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., Sueiro, M. R., Lambert, C., Gussoni, G., Campanini, M., Fontanella, A., Vescovo, G., & Verso, M. (2020). Apixaban for the treatment of venous thromboembolism associated with cancer. *New England Journal of Medicine, 382*(17), 1599–1607. https://doi.org/10.1056/NEJMoa1915103

American Heart Association. (2026, February 19). *2026 guideline for the evaluation and management of acute pulmonary embolism in adults* [Guideline science summary]. https://professional.heart.org/en/science-news/2026-guideline-for-the-evaluation-and-management-of-acute-pulmonary-embolism-in-adults

Barnes, G. D. (2020, July 14). *ACC consensus on management of anticoagulant-related bleeding* [Key points from the ACC expert consensus pathway]. American College of Cardiology. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/07/10/11/26/2020-acc-expert-consensus-decision-pathway-on-bleeding

Boehringer Ingelheim Pharmaceuticals, Inc. (2025). *Pradaxa (dabigatran etexilate mesylate) capsules* [U.S. prescribing information, revised June 2025]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9

Bristol Myers Squibb & Pfizer. (2026). *Eliquis (apixaban)* [U.S. prescribing information, revised August 2026]. https://packageinserts.bms.com/pi/pi_eliquis.pdf

Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S.,

Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H.-C., Joyner, C. D., & Wallentin, L. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine, 361*(12), 1139–1151. https://doi.org/10.1056/NEJMoa0905561

Crawford, T. C. (2023, November 30). *2023 guideline for diagnosis and management of atrial fibrillation: Key perspectives.* American College of Cardiology. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af

Daiichi Sankyo, Inc. (2023). *Savaysa (edoxaban)* [U.S. prescribing information, revised October 2023]. https://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true

Douketis, J. D., Spyropoulos, A. C., Duncan, J., Carrier, M., Le Gal, G., Tafur, A. J., Vanassche, T., Verhamme, P., Shivakumar, S., Gross, P. L., Lee, A. Y. Y., Yeo, E., Solymoss, S., Kassis, J., Le Templier, G., Kowalski, S., Blostein, M., Shah, V., MacKay, E., … Schulman, S. (2019). Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. *JAMA Internal Medicine, 179*(11), 1469–1478. https://doi.org/10.1001/jamainternmed.2019.2431

Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., Grip, L. T., Patel, S. P., Patel, I., Hanyok, J. J., … Antman, E. M. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine, 369*(22), 2093–2104. https://doi.org/10.1056/NEJMoa1310907

Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., … Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine, 365*(11), 981–992. https://doi.org/10.1056/NEJMoa1107039

Janssen Pharmaceuticals, Inc. (2026). *Xarelto (rivaroxaban)* [U.S. prescribing information, revised March 2026]. https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf

Kopp, S. L., Vandermeulen, E., McBane, R. D., Perlas, A., Leffert, L., & Horlocker, T. (2025). Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fifth edition). *Regional Anesthesia and Pain Medicine.* Advance online publication. https://doi.org/10.1136/rapm-2024-105766

Lopes, R. D., Heizer, G., Aronson, R., Vora, A. N., Massaro, T., Mehran, R., Goodman, S. G., Windecker, S., Darius, H., Li, J., Averkov, O., Bahit, M. C., Berwanger, O., Budaj, A., Hijazi, Z., Parkhomenko, A., Sinnaeve, P., Storey, R. F., Thiele, H., … Alexander, J. H. (2019). Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *New England Journal of Medicine, 380*(16), 1509–1524. https://doi.org/10.1056/NEJMoa1817083

Mahé, I., Carrier, M., Mayeur, D., Chidiac, J., Vicaut, E., Falvo, N., Sanchez, O., Grange, C., Monreal, M., López-Núñez, J. J., Otero-Candelera, R., Le Gal, G., Yeo, E., Righini, M., Robert-Ebadi, H., Huisman, M. V., Klok, F. A., Westerweel, P., Agnelli, G., … Laporte, S. (2025). Extended reduced-dose apixaban for cancer-associated venous thromboembolism. *New England Journal of Medicine, 392*(14), 1363–1373. https://doi.org/10.1056/NEJMoa2416112

Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A. A., & Califf, R. M. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *New England Journal of Medicine, 365*(10), 883–891. https://doi.org/10.1056/NEJMoa1009638

Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., Sinnaeve, P., Vanassche, T., Potpara, T., Camm, A. J., & Heidbüchel, H. (2021). 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Europace, 23*(10), 1612–1676. https://doi.org/10.1093/europace/euab065

U.S. Food and Drug Administration. (2025, December 18). *Update on the safety of Andexxa.* https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/update-safety-andexxa